Stockscreener 앱 받기
70.07
2.73%
-1.97
전일 마감가:
$72.04
열려 있는:
$72.1
하루 거래량:
942.42K
Relative Volume:
0.62
시가총액:
$4.95B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-31.56
EPS:
-2.22
순현금흐름:
$-105.32M
1주 성능:
-6.47%
1개월 성능:
-10.07%
6개월 성능:
+265.71%
1년 성능:
+187.53%
1일 변동 폭
$69.95
$73.33
1주일 범위
$69.95
$81.15
52주 변동 폭
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(650) 457-1978
주소
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
70.07 | 5.09B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
(GPCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FY2030 Earnings Forecast for GPCR Issued By HC Wainwright - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), CSL (CMXHF) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Federated Hermes Inc. - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation As Oral Obesity Drug GSBR-1290 Advances In Phase 2 - Sahm
Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics’ Oral Obesity Drug Enters Phase 2 As Investor Focus Grows - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Down 10.7%Here's Why - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
UPDATE 3-Novo Nordisk warns on profits and sales amid Trump drug price crackdown - Sahm
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Responsive Playbooks and the GPCR Inflection - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Viking Therapeutics (VKTX) - The Globe and Mail
CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Genentech Licensing Deal and Guggenheim Reaffirmation Could Be A Game Changer For Structure Therapeutics (GPCR) - Sahm
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Raised to "Strong-Buy" at The Goldman Sachs Group - MarketBeat
Understanding the Setup: (GPCR) and Scalable Risk - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence - Sahm
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
Goldman Sachs Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $102 - 富途资讯
Why Structure Therapeutics Stock Is Breaking Out Now - TipRanks
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7% - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
SG Americas Securities LLC Has $1.11 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN) - The Globe and Mail
Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" - Finviz
Structure Therapeutics (GPCR) Is Up 26.9% After Strong Obesity Pill Data And $748 Million OfferingWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Finviz
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Finviz
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Watch Structure Therapeutics CEO Stevens on Pipeline Strategy - Bloomberg.com
Structure Therapeutics Stock Surges Amid Positive Analyst Ratings - StocksToTrade
Janney Capital Management LLC Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - AOL.com
Structure Therapeutics (NASDAQ:GPCR) Trading 12.2% HigherShould You Buy? - MarketBeat
Price Target Hike Sparks Optimism for Structure Therapeutics - StocksToTrade
Why Structure Therapeutics Shares Are Surging Now - TipRanks
Assessing Structure Therapeutics (GPCR) Valuation After Obesity Trial Progress And Genentech Licensing Deal - Sahm
Structure Therapeutics inks major GLP-1 licensing deal - MSN
The Technical Signals Behind (GPCR) That Institutions Follow - Stock Traders Daily
Can This Stock Double Again in 2026? - Finviz
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - sharewise.com
Genentech Licensing Deal For Oral Obesity Drug CT-996 Might Change The Case For Investing In Structure Therapeutics (GPCR) - Sahm
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):